Skip to Content

Newsroom

M. D. Anderson STAR Anniversary Luncheon Honors Participants in Breast Cancer Prevention Research

M. D. Anderson STAR Anniversary Luncheon Honors Participants in Breast Cancer Prevention Research
M. D. Anderson News Release 10/03/02

More than 200 people attended the 10th annual luncheon for participants in the Study of Tamoxifen and Raloxifene (STAR) and the Breast Cancer Prevention Trial (BCPT).

Researchers at The University of Texas M. D. Anderson Cancer Center honored women who completed five years of participation in the landmark tamoxifen research study during the awards luncheon held Sept. 28, at the Junior League of Houston.  Each of the women who, this year, completed all five years of participation was recognized.

Judy Jordan, STAR participant and national Participant Advisory Board member, shared how her status as high-risk for breast cancer motivated her to become active in breast cancer prevention research.  Jordan also participated in the STAR forerunner, BCPT, the study that showed for the first time that tamoxifen can prevent breast cancer.

Funded by the National Cancer Institute, STAR is a follow-up study to the groundbreaking BCPT study that demonstrated that tamoxifen can prevent breast cancer in women at high risk for the disease.  The

NCI is recruiting 22,000 women nationwide to participate in STAR during the five-year enrollment period ending in 2004, up from the more than 13,000 women recruited for BCPT.

M. D. Anderson is seeking to enroll 400 women and is encouraging women to join STAR.  Once a woman decides to participate, she is randomly assigned to receive either tamoxifen or raloxifene daily for five years.  Every woman receives regular follow-up examinations.

Postmenopausal women interested in STAR may call M. D. Anderson’s “STAR line” at (713) 792-8064 or visit the STAR website.

10/03/02


© 2014 The University of Texas MD Anderson Cancer Center